This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
Cancer				
Cancer	CD3; folate receptor	<i>In vitro</i> and mouse studies suggest an anti-CD3 antibody conjugated to folic acid could help treat cancer. The antibody conjugate specifically bound folate receptor-expressing tumor cells and was cytotoxic when cultured with peripheral blood mononuclear cells (PBMCs). In mice with folate receptor-positive nasopharyngeal cancer xenografts, the conjugate plus human PBMCs decreased tumor volume compared with saline plus PBMCs. Next steps include safety studies. This work was performed in collaboration with Ambrx Inc., and the development status of the antibody was not disclosed. SciBX 6(42); doi:10.1038/scibx.2013.1183 Published online Oct. 31, 2013	Patent and licensing status unavailable	Kularatne, S.A. <i>et al. Angew. Chem. Int. Ed.</i>; published online Sept. 25, 2013; doi:10.1002/anie.201306866 Contact: Peter G. Schultz, The Scripps Research Institute, La Jolla, Calif. e-mail: schultz@scripps.edu